Adeno-associated virus vectors: potential applications for cancer gene therapy.
Augmenting cancer treatment by protein and gene delivery continues to gain momentum based on success in animal models. The primary hurdle of fully exploiting the arsenal of molecular targets and therapeutic transgenes continues to be efficient delivery. Vectors based on adeno-associated virus (AAV) are of particular interest as they are capable of inducing transgene expression in a broad range of tissues for a relatively long time without stimulation of a cell-mediated immune response. Perhaps the most important attribute of AAV vectors is their safety profile in phase I clinical trials ranging from CF to Parkinson's disease. The utility of AAV vectors as a gene delivery agent in cancer therapy is showing promise in preclinical studies. In this review, we will focus on the basic biology of AAV as well as recent progress in the use of this vector in cancer gene therapy.
Li
Chengwen
C
Gene Therapy Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC 27599, USA.
Bowles
Dawn E
DE
van Dyke
Terry
T
Samulski
Richard Jude
RJ
D000818:Animals; D000229:Dependovirus / Q000235:genetics*; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000235:genetics* / Q000276:immunology / Q000628:therapy*